MedTrace Logo

A Study of Chimeric Antigen Receptor T Cells Combined With Interventional Therapy in Advanced Liver Malignancy

NCT02959151 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2016-11-08

No results posted yet for this study

Summary

The purpose of this study is to collect the date on the safety and potential effectiveness of CART cells combined with interventional therapy in patients with advanced liver malignancy.

Conditions

  • Carcinoma, Hepatocellular
  • Pancreatic Cancer Metastatic
  • Colorectal Cancer Metastatic

Interventions

DRUG

CAR-T cell

CAR-T cells are generated by T cells from the patients or a suitable donor transfected by CAR-lentivirus vectors. There are three options for CAR-targets: GPC3 for hepatocellular carcinoma;mesothelin for pancreatic cancer metastatic; CEA for colorectal cancer metastatic.

Sponsors & Collaborators

  • Shanghai Cancer Hospital, China

    collaborator OTHER

  • Shanghai GeneChem Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Wentao Li, doctor · Fudan University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
69 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-07-31
Primary Completion
2018-01-31
Completion
2018-07-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02959151 on ClinicalTrials.gov